Elanco Animal Health Incorporated (ELAN) Is A Bargain Stock You …

Elanco Animal Health Incorporated (NYSE:ELAN) has a beta value of 0.97 and has seen 6.67 million shares traded in the last trading session. The company, currently valued at £4.37B, closed the last trade at £8.93 per share which meant it lost -£0.16 on the day or -1.76% during that session. The ELAN stock price is -209.07% off its 52-week high price of £27.60 and 2.8% above the 52-week low of £8.68.

If we look at the company’s 10-day average daily trading volume, we find that it stood at 11.52 million shares traded. The 3-month trading volume is 7.70 million shares. The consensus among analysts is that Elanco Animal Health Incorporated (ELAN) is a Hold stock at the moment, with a recommendation rating of 2.80.

1 analysts rate the stock as a Sell, while 0 rate it as Overweight.

8 out of 12 have rated it as a Hold, with 3 advising it as a Buy.

0 have rated the stock as Underweight. The expected earnings per share for the stock is £0.13. Sporting -1.76% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Tuesday, 03/28/23 when the ELAN stock price touched £8.93 or saw a rise of 5.8%.

Year-to-date, Elanco Animal Health Incorporated shares have moved -26.92%, while the 5-day performance has seen it change -5.70%. Over the past 30 days, the shares of Elanco Animal Health Incorporated (NYSE:ELAN) have changed -22.95%. Short interest in the company has seen 21.17 million shares shorted with days to cover at 2.93.

Wall Street analysts have a consensus price target for the stock at £15.06, which means that the shares’ value could jump 40.7% from current levels. The projected low price target is £10.50 while the price target rests at a high of £20.00. In that case, then, we find that the current price level is -123.96% off the targeted high while a plunge would see the stock gain -17.58% from current levels.

Elanco Animal Health Incorporated (ELAN) estimates and forecasts

Figures show that Elanco Animal Health Incorporated shares have underperformed across the wider relevant industry.

The company’s shares have lost -29.46% over the past 6 months, with this year growth rate of -29.73%, compared to 0.90% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are -38.10% and -8.30% for the next quarter.

Revenue growth from the last financial year stood is estimated to be -7.40%.

8 analysts offering their estimates for the company have set an average revenue estimate of £980.94 million for the current quarter.

6 have an estimated revenue figure of £1.16 billion for the next quarter concluding in Mar 2023. Year-ago sales stood £1.11 billion and £1.23 billion respectively for this quarter and the next, and analysts expect sales will shrink by -11.90% for the current quarter and -5.50% for the next. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 30.20% over the past 5 years.

Earnings growth for 2023 is a modest 83.90% while over the next 5 years, the company’s earnings are expected to increase by 7.00%.

ELAN Dividends

Elanco Animal Health Incorporated is expected to release its next earnings report between May 08 and May 12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Elanco Animal Health Incorporated (NYSE:ELAN)’s Major holders

Insiders own 0.27% of the company shares, while shares held by institutions stand at 99.29% with a share float percentage of 99.57%. Investors are also buoyed by the number of investors in a company, with Elanco Animal Health Incorporated having a total of 617 institutions that hold shares in the company. The top two institutional holders are Dodge & Cox Inc with over 53.0 million shares worth more than £657.75 million.

As of Sep 29, 2022, Dodge & Cox Inc held 11.18% of shares outstanding. The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 42.68 million shares as of Sep 29, 2022. The firm’s total holdings are worth over £529.61 million and represent 9.00% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Dodge & Cox Stock Fund and Vanguard/Primecap Fund.

As of Dec 30, 2022, the former fund manager holds about 11.58% shares in the company for having 54.9 million shares of worth £670.92 million while later fund manager owns 13.51 million shares of worth £167.62 million as of Sep 29, 2022, which makes it owner of about 2.85% of company’s outstanding stock.